Safety and clinical activity of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC)

被引：10

作者：

Antonia, Scott ^{[1
]}

Rizvi, Naiyer ^{[2
]}

Brahmer, Julie ^{[3
]}

Ou, Sai-Hong ^{[4
]}

Khleif, Samir N. ^{[5
]}

Hwu, Wen-Jen ^{[6
]}

Gutierrez, Martin ^{[7
]}

Schoffski, Patrick ^{[8
]}

Hamid, Omid ^{[9
]}

Weiss, Jared ^{[10
]}

Lutzky, Jose ^{[11
]}

Maio, Michele ^{[12
]}

Nemunaitis, John ^{[13
]}

Jaeger, Dirk ^{[14
]}

Balmanoukian, Ani ^{[9
]}

Rebelatto, Marlon C. ^{[15
]}

Steele, Keith E. ^{[15
]}

Jin, Xiaoping ^{[15
]}

Robbins, Paul B. ^{[15
]}

Blake-Haskins, John A. ^{[15
]}

Segal, Neil H. ^{[16
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[2] Columbia Univ, Med Ctr, New York, NY USA

[3] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA

[4] Univ Calif Irvine, Sch Med, Irvine, CA 92717 USA

[5] Georgia Regent Univ, GRU Canc Ctr, Agusta, MD USA

[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[7] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[8] Leuven Canc Inst, Leuven, Belgium

[9] Angeles Clin & Res Inst, Los Angeles, CA USA

[10] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA

[11] Mt Sinai Med Ctr, New York, NY 10029 USA

[12] Univ Hosp Siena, Siena, Italy

[13] Mary Crowley Canc Res Ctr, Dallas, TX USA

[14] Univ Heidelberg Hosp, Natl Ctr Tumor Dis, Heidelberg, Germany

[15] Medlmmune, Gaithersburg, MD USA

[16] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

CANCER IMMUNOLOGY RESEARCH | 2016年 / 4卷 / 01期

关键词：

D O I：

10.1158/2326-6074.CRICIMTEATIAACR15-A047

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A047

引用

页数：2

共 50 条

[31] Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis
Liang, Jiaqi
Li, Ming
Sui, Qihai
Hu, Zhengyang
Bian, Yunyi
Huang, Yiwei
Zhan, Cheng
Jiang, Wei
Wang, Qun
Tan, Lijie
TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (04) : 1302 - +
[32] Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naive patients (pts) with EGFR mutant NSCLC
Gibbons, D. L.
Chow, L. Q.
Kim, D-W.
Kim, S-W.
Yeh, T.
Song, X.
Jiang, H.
Taylor, R.
Karakunnel, J.
Creelan, B.
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S79 - S79
[33] An immunohistochemical PD-L1 companion diagnostic assay for treatment with durvalumab (MEDI4736) in NSCLC patients
Rebelatto, Marlon C.
Mistry, Amita
Sabalos, Constantine
Schechter, Nicole
Walker, Jill
Midha, Anita
Steele, Keith E.
Robbins, Paul B.
Li, Xia
Shi, Li
Blake-Haskins, John A.
Ibrahim, Ramy A.
Richman, Laura
CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
[34] Safety and efficacy of durvalumab (MEDI4736) plus tremelimumab in advanced non-small-cell lung cancer (NSCLC)
Karakunnel, Joyson J.
ANNALS OF ONCOLOGY, 2016, 27
[35] The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population
Skov, Birgit Guldhammer
Rorvig, Sara Bird
Jensen, Thomas Hartvig Lindkaer
Skov, Torsten
MODERN PATHOLOGY, 2020, 33 (01) : 109 - 117
[36] Immunotherapy efficacy of programmed cell death 1 (PD-1) versus programmed death ligand-1 (PD-L1) inhibitors in non-small cell lung cancer (NSCLC) patients: A systematic review and meta-analysis.
Yang, Danrong
Cui, Longgang
Zhang, Yuzi
Zhao, Zhengyi
Bai, Yuezong
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[37] Spatiotemporal Effects on Programmed Death Ligand 1 (PD-L1) Expression and Immunophenotype of Non-Small Cell Lung Cancer (NSCLC)
Kowanetz, Marcin
Koeppen, Hartmut
Boe, Marigold
Chaft, Jamie E.
Rudin, Charles M.
Zou, Wei
Nickles, Dorothee
Desai, Rupal
Nakamura, Rin
Sandler, Alan
Amler, Lukas
Hegde, Priti
Rizvi, Naiyer A.
Hellmann, Matthew D.
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S199 - S199
[38] Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment-are we barking up the wrong tree?
Dempke, Wolfram C. M.
Fenchel, Klaus
Dale, Stephen P.
TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S275 - S279
[39] Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management
Shen, John
Chang, Jason
Mendenhall, Melody
Cherry, Grace
Goldman, Jonathan W.
Kulkarni, Rajan P.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
[40] Programmed death ligand-1 expression in non-small cell lung cancer
Velcheti, Vamsidhar
Schalper, Kurt A.
Carvajal, Daniel E.
Anagnostou, Valsamo K.
Syrigos, Konstantinos N.
Sznol, Mario
Herbst, Roy S.
Gettinger, Scott N.
Chen, Lieping
Rimm, David L.
LABORATORY INVESTIGATION, 2014, 94 (01) : 107 - 116

← 1 2 3 4 5 →